Genetic Technologies Announces Strategic Alliance and Capital Raising

Genetics Investing

Genetic Technologies (NASDAQ:GENE) a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, is pleased to announce that it has entered into a non-binding terms sheet with Blockchain Global Limited ACN 601 628 497. As quoted in the press release: Dr Paul Kasian, Genetic Technologies’ …

As quoted in the press release:

Dr Paul Kasian, Genetic Technologies’ newly elected Chairman of the Board, commented: “The Board is extremely excited about the opportunities that the agreement with Blockchain Global presents to not only build on the wonderful assets and expertise that the Company has developed to date, but also take advantage of the new and developing opportunities before us. The merging of genomics and global digital platforms will create exciting opportunities. Blockchain is a trusted digital ledger that provides a secure low cost and fast way to gather and disseminate information and we look forward to exploring its potential application in genomics to improve personalised health.”

Click here to read the full press release.

application blockchain breast cancer cancer diagnostics diagnostics company genetic technologies genomics health molecular diagnostics Genetics Investing